reports
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025. Sanofi annonce aujourd’hui la finalisation de . Cette acquisition apporte à Sanofi un candidat-vaccin combiné en phase précoce de développement contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV), deux virus respiratoires, et renforce les capacités de conception et de développement de vaccins grâce à la technologie « Molecular Clamp » de Vicebio. Le candidat-vaccin acquis complète la position de Sanofi dans le domaine des vaccins ...
Press Release: Sanofi completes acquisition of Vicebio
Press Release: Sanofi completes acquisition of Vicebio Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its . This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in...
- Research Department
IBERIAN DAILY 01 DECEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: IAG, MAPFRE, SANTANDER, TELEFÓNICA. Between monetary policy and a possible Ukraine-Russia peace treaty With the only US macro reference being the Fed’s Beige Book, the markets saw a transitional week due to Black Friday. European markets ended the week with gains, rallying from support levels and seeking 2025 highs, with the Ukraine-Russia peace talks continuing to be in the spotlight. In the STOXX 600, Basic Resources and Construction led the gains, with Food and Household Goods ...
- Research Department
INFORME DIARIO 01 DICIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IAG, MAPFRE, SANTANDER, TELEFÓNICA. EUROPA: AIRBUS. Entre la política monetaria y una posible paz en Ucrania/Rusia Los mercados vivieron una semana de transición por el Black Friday y ante escasas referencias macroeconómicas. A la espera de las negociaciones de Paz entre Ucrania y Rusia las bolsas europeas terminaron la semana con ganancias, buscando los máximos del año. En el STOXX 600, las ganancias fueron dirigidas por Recursos Básicos seguido de...
- Carole Braudeau
Credit Morning 11/26/2025
Celanese’s CFR downgraded by Moody’s with the outlook still negative|Plan to transfer all Auchan supermarkets to the Intermarché and Netto brands via a franchise agreement.|Mobilux: Q1 earnings down sharply but no leverage impact thanks to strong cash generation|Forvia: bids expected this week for the Interiors division, with a valuation of € 1.8-2.0bn|
- Carole Braudeau
Morning Crédit 26/11/2025
Celanese’s CFR downgraded by Moody’s with the outlook still negative|Projet de passage de tous les supermarchés Auchan sous enseigne Intermarché et Netto via un contrat de franchise|Mobilux : des résultats T1 en net repli mais sans impact levier grâce à une forte génération de cash|Forvia : des offres attendues cette semaine pour la division Interiors, avec une valorisation de 1.8-2.0 mds EUR|
- Research Department
IBERIAN DAILY 26 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, FERROVIAL, NEINOR, TELEFÓNICA. Stock markets remain confident that the Fed will end up cutting rates European stock markets rose, welcoming higher rate cut expectations in the Fed’s next meeting, especially after the weakness of the US data released yesterday. In the STOXX 600, Construction and Retail were the best performers whereas cyclicals sectors such as Technology and Energy posted the biggest drop. On the macro side, in the US September’s retail sa...
- Research Department
INFORME DIARIO 26 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, FERROVIAL, NEINOR HOMES, TELEFÓNICA. EUROPA: ENI, UNICREDIT. Confianza en que la Fed terminará bajando tipos Avances en las bolsas europeas, que siguen celebrando las mayores expectativas de bajadas de tipos para la próxima reunión de la Fed, especialmente después de la debilidad de los datos estadounidenses de hoy. En el STOXX 600, los mejores sectores fueron Construcción y Retail mientras que cíclicos como Tecnología y En...
- Research Department
INFORME DIARIO 25 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: BANKINTER, IBERDROLA, TELEFÓNICA, VISCOFAN. El mercado coge aire Ligero rebote en las bolsas europeas, ante los progresos en las negociaciones de paz en Ucrania y las expectativas de bajadas de tipos para la próxima reunión de la Fed. En el STOXX 600, los mejores sectores fueron cíclicos como R. Básicos y Ocio mientras que Media y Hogar sufrieron las mayores correcciones. Por el lado macro, en Alemania el IFO de noviembre retrocedió de forma inespe...
- Research Department
IBERIAN DAILY 25 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: BANKINTER, IBERDROLA, TELEFÓNICA, VISCOFAN. Stock markets take a break European stock markets saw a slight rally amid progress in the peace negotiations in Ukraine and rate cut expectations in the Fed’s next meeting. In the STOXX 600, cyclicals sectors such as Basic Resources and Leisure were the best performers whereas Media and Household posted the biggest drop. On the macro side, in Germany November’s IFO fell unexpectedly, with drops in the expectations component. In Europe, v...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first t...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which i...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a ...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...
- Ben Rickett
- James Ratzer
FWA is on the horizon It has the potential to be disruptive: Keep a v...
FWA has reached 38% penetration in Austria today, 13% in Italy, but is just 1-2% elsewhere in Europe. Furthermore, the EC has just made a major decision to dedicate a further 540MHz of spectrum to mobile carriers increasing their bandwidth by 60%.
- Carole Braudeau
Credit Morning 11/21/2025
Tereos : -66% EBITDA in H1 25/26 and expected leverage slippage to 6x in March 2026|Ubisoft: net bookings above expectations in Q2 2025/26. The group breached covenants of certain debt, some of which will be repaid using proceeds from the closing of the JV with Tencent|Orange/Iliad/Bouygues are reportedly mulling a wider offer for SFR (Financial Times)|
- Carole Braudeau
Morning Crédit 21/11/2025
Tereos : Résultats S1 25/26 : -66% d’EBITDA au S1 25/26 et dérapage attendu du levier à 6x en mars 2026|Ubisoft (UBIFP, non noté) : net bookings supérieurs aux attentes au T2 2025/26, la guidance annuelle est confirmée. Le groupe a brisé les covenants de certaines dettes qui seront remboursées grâce aux produits de la finalisation de la JV avec Tencent.|Orange/Iliad/Bouygues envisageraient une offre élargie sur SFR (Financial Times)|
- Research Department
INFORME DIARIO 21 NOVIEMBRE (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAF, TELEFÓNICA, UNICAJA. EUROPA: PROSUS. Nvidia, un impulso a las bolsas que se desinfla Los resultados publicados por la tecnológica disipan de momento las dudas en torno a la IA y provocó rebotes en los índices europeos superiores al 1% pero que se fueron moderando hacia el cierre del mercado con un Ibex que se quedó al borde de los 16.000 puntos. En el STOXX 600, Energía e Industriales fueron los que mayores ganancias presentaron frente a Autos...
- Research Department
IBERIAN DAILY 21 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: CAF, TELEFÓNICA, UNICAJA. Nvidia fuelled stock markets to later ease The results released by the technology group dispelled doubts surrounding AI for the time being, leading to the rally of European markets >1% that eased at the closing bell, with the Ibex near 16,000 points. In the STOXX 600, Energy and Industrial led gains vs. Autos and Media that posted the biggest drops. On the macro side, in the euro zone, December’s consumer confidence was disappointing after remaining at th...
- Research Department
IBERIAN DAILY 17 NOVEMBER + 3Q’25 RESULTS. PREVIEWS (ANÁLISIS BANCO SA...
NEWS SUMMARY: ACS, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Fear of AI bubble brings volatility Following the record highs reached last week thanks to the hope of an end to the shutdown in the US and the solid business results, stock markets reeled in part of the gains due to the concerns of a bubble...
- Research Department
INFORME DIARIO 17 NOVIEMBRE + RDOS. ESPAÑA 3T’25. PREVIEWS (ANÁLISIS B...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, TELEFÓNICA. EUROPA: AIRBUS, PROSUS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. El temor a una burbuja en la IA genera volatilidad en las bolsas Tras los máximos históricos alcanzados en la semana gracias a la esperanza de una resoluci...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CH...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris, November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.